Metroticket 2.0模型用于分析肝细胞癌肝移植后竞争性死亡风险
研究基于意大利3个中心1018例及上海341例肝细胞癌肝移植患者,采用竞争风险回归分析,发现肿瘤数目与大小之和及甲胎蛋白(AFP)对数值与HCC特异性死亡显著相关,据此建立Metroticket 2.0模型,用于预测5年HCC特异性生存并辅助选择移植标准。
要点
- 肿瘤数目与大小之和及log10 AFP与HCC特异性死亡显著相关(P < .001)。
- 模型预测5年HCC特异性生存的平均c-statistic为0.780(95%CI 0.763-0.798)。
- 验证集准确度为0.721(95%CI 0.648%-0.793%),优于米兰等标准(P < .001)。
核心结论
- 基于AFP水平、肿瘤大小和肿瘤数目的模型可用于确定肝移植后HCC相关因素导致的死亡风险。
- 该模型可能用于选择终点和优化HCC患者肝移植的选择标准。
研究设计与样本
- 多变量竞争风险回归分析,训练集为2000年1月至2013年12月意大利3个三级中心1018例因HCC行肝移植的患者。
- 验证集为同期中国上海肝癌研究所341例连续因HCC行肝移植的患者。
- 收集移植前数据包括肝病病因、肿瘤数目和大小、AFP水平、MELD评分、肿瘤分期、治疗次数和类型、治疗反应、肿瘤分级、微血管侵犯、日期和死亡原因。
主要发现
- 竞争风险回归中,肿瘤数目与大小之和及log10 AFP水平与HCC特异性死亡显著相关(P < .001),平均c-statistic为0.780(95%CI 0.763-0.798)。
- HCV阴性患者5年非HCC相关死亡累积发生率为8.6%,HCV阳性患者为18.1%。
- 为使移植后5年HCC特异性生存概率达70%,AFP <200 ng/mL时肿瘤数目与大小(厘米)之和应不超过7;AFP 200-400 ng/mL时应≤5;AFP 400-1000 ng/mL时应≤4。
- 验证集中模型识别肝移植后生存5年患者的准确度为0.721(95%CI 0.648%-0.793%)。
- 模型预测5年生存优于米兰、加州大学旧金山、上海复旦、Up-to-7标准(P < .001)及AFP French模型(P = .044)。
关键数值与推荐
- 移植后5年HCC特异性生存概率达70%的条件:AFP <200 ng/mL且肿瘤数目与大小之和≤7 cm。
- AFP 200-400 ng/mL时肿瘤数目与大小之和应≤5 cm;AFP 400-1000 ng/mL时应≤4 cm。
- 模型预测5年HCC特异性生存的平均c-statistic为0.780(95%CI 0.763-0.798)。
- 验证集准确度为0.721(95%CI 0.648%-0.793%)。
临床怎么用
- 作者认为该模型可能用于选择终点和优化HCC患者肝移植的选择标准。
- 可通过在线计算器www.hcc-olt-metroticket.org/预测5年生存和HCC相关死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Outcomes of liver transplantation for hepatocellular carcinoma (HCC) are determined by cancer-related and non-related events. Treatments for hepatitis C virus infection have reduced non-cancer events among patients receiving liver transplants, so reducing HCC-related death might be an actionable end point. We performed a competing-risk analysis to evaluate factors associated with survival of patients with HCC and developed a prognostic model based on features of HCC patients before liver transplantation. METHODS: We performed multivariable competing-risk regression analysis to identify factors associated with HCC-specific death of patients who underwent liver transplantation. The training set comprised 1018 patients who underwent liver transplantation for HCC from January 2000 through December 2013 at 3 tertiary centers in Italy. The validation set comprised 341 consecutive patients who underwent liver transplantation for HCC during the same period at the Liver Cancer Institute in Shanghai, China. We collected pretransplantation data on etiology of liver disease, number and size of tumors, patient level of α-fetoprotein (AFP), model for end-stage liver disease score, tumor stage, numbers and types of treatment, response to treatments, tumor grade, microvascular invasion, dates, and causes of death. Death was defined as HCC-specific when related to HCC recurrence after transplantation, disseminated extra- and/or intrahepatic tumor relapse and worsened liver function in presence of tumor spread. The cumulative incidence of death was segregated for hepatitis C virus status. RESULTS: In the competing-risk regression, the sum of tumor number and size and of log10 level of AFP were significantly associated with HCC-specific death (P < .001), returning an average c-statistic of 0.780 (95% confidence interval, 0.763-0.798). Five-year cumulative incidence of non-HCC-related death was 8.6% in HCV-negative patients and 18.1% in HCV-positive patients. For patients with HCC to have a 70% chance of HCC-specific survival 5 years after transplantation, their level of AFP should be <200 ng/mL and the sum of number and size of tumors (in centimeters) should not exceed 7; if the level of AFP was 200-400 ng/mL, the sum of the number and size of tumors should be ≤5; if their level of AFP was 400-1000 ng/mL, the sum of the number and size of tumors should be ≤4. In the validation set, the model identified patients who survived 5 years after liver transplantation with 0.721 accuracy (95% confidence interval, 0.648%-0.793%). Our model, based on patients' level of AFP and HCC number and size, outperformed the Milan; University of California, San Francisco; Shanghai-Fudan; Up-to-7 criteria (P < .001); and AFP French model (P = .044) to predict which patients will survive for 5 years after liver transplantation. CONCLUSIONS: We developed a model based on level of AFP, tumor size, and tumor number, to determine risk of death from HCC-related factors after liver transplantation. This model might be used to select end points and refine selection criteria for liver transplantation for patients with HCC. To predict 5-year survival and risk of HCC-related death using an online calculator, please see www.hcc-olt-metroticket.org/. ClinicalTrials.gov ID NCT02898415.
引用
- Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology. 2017. PMID: 28989060. doi:10.1053/j.gastro.2017.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。